Aquestive Therapeutics forecasts 2026 revenue of $46 million-$50 million

Bitget2026/11/04 14:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aquestive Therapeutics forecasts 2026 revenue of $46 million-$50 million in its November 3 outlook.
Non-GAAP adjusted EBITDA loss is projected at $30 million-$35 million.
Third-quarter cash totaled $90.3 million, down from $98.5 million in the second quarter.
An October Libervant out-licensing deal generated $10 million upfront, with potential contingent milestone payments totaling $47.5 million.
Anaphylm’s potential launch is targeted for the second quarter of 2027, subject to FDA approval; its review goal date is March 16.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aquestive Therapeutics forecasts 2026 revenue of $46 million-$50 million

You may also like

Crypto prices